infecti
diseas
pose
greatest
threat
public
health
result
year
life
lost
prematur
death
diseas
prior
centuri
infect
syndrom
often
describ
better
artist
writer
scientist
began
chang
microb
better
understood
past
year
mani
ancient
diseas
smallpox
polio
measl
explain
control
howev
past
three
decad
constant
stream
newli
identifi
pathogen
receiv
increas
attent
approach
new
pandem
threat
gener
reactiv
specif
medic
intervent
avail
time
make
substanti
impact
immedi
outbreak
technic
advanc
provid
tool
made
proactiv
approach
feasibl
critic
determin
achiev
sustain
develop
goal
sdg
establish
un
unit
nation
tabl
introduct
emerg
infecti
diseas
eid
human
popul
often
consequ
econom
develop
bring
zoonot
reservoir
closer
proxim
peopl
spread
eid
contribut
number
interrel
factor
affect
global
human
well
notabl
control
infecti
diseas
interdepend
progress
toward
un
therefor
prevent
prepared
epidem
conduct
context
meet
sdg
acceler
appear
new
infecti
diseas
threat
pandem
potenti
reflect
establish
world
health
organ
emerg
committe
sinc
four
public
health
emerg
intern
concern
declar
involv
pandem
influenza
polio
resurg
ebola
epidem
west
africa
emerg
zika
viru
america
whether
frequenc
amplifi
increas
global
commerc
travel
disrupt
ecolog
conflict
econom
develop
bring
human
contact
previous
unrecogn
pathogen
human
face
perpetu
microbi
challeng
increas
occurr
pandem
threat
global
eid
caus
virus
either
zoonot
vectorborn
antimicrobi
resist
also
consider
concern
prospect
pandem
spread
bacteri
fungal
pathogen
seem
less
like
nonetheless
spread
diseas
plagu
cholera
tuberculosi
recent
legionnair
diseas
invas
streptococc
diseas
toxicshock
syndrom
would
present
consider
risk
thu
need
rapid
diagnosi
definit
transmiss
pathway
avail
antimicrobi
agent
focu
newli
emerg
viral
diseas
particularli
identifi
past
three
decad
mobil
human
transmiss
vector
virus
steep
upward
trajectori
consid
immunolog
tool
new
technolog
could
help
address
problem
improv
scientif
prepared
next
pandem
threat
divid
four
broad
categori
consid
turn
establish
central
infrastructur
highthroughput
sequenc
region
high
biolog
divers
new
human
infect
like
occur
allow
rapid
detect
emerg
pathogen
center
could
also
serv
hub
deploy
resourc
unexpect
locat
respons
new
outbreak
infrastructur
technolog
could
use
probe
environ
ongo
basi
defin
spectrum
viral
strain
speci
exist
within
phylogenet
famili
known
infect
human
thoroughli
defin
exist
virus
via
highthroughput
sequenc
improv
capac
surveil
leverag
improv
develop
diagnost
technolog
converg
justifi
invest
facil
personnel
train
combin
improv
surveil
diagnost
enhanc
region
patient
care
sustain
technic
compet
prototyp
virus
within
main
famili
virus
caus
human
infect
need
develop
morecomprehens
set
reagent
includ
monoclon
antibodi
recogn
surfac
protein
intern
protein
would
allow
develop
antigenspecif
assay
provid
standard
earli
develop
serolog
assay
also
involv
defin
key
antigen
target
protect
antibodi
solv
structur
surfac
glycoprotein
develop
serolog
assay
measur
function
activ
either
recombin
pseudotyp
report
virus
feasibl
identifi
cellular
receptor
tropism
basic
inform
would
provid
toolbox
need
defin
mechan
neutral
develop
anim
model
pathogenesi
determin
whether
replic
restrict
entri
receptor
exampl
betacoronavirus
innat
cellular
factor
exampl
human
immunodefici
viru
type
failur
inhibit
interferon
exampl
flavivirus
paramyxovirus
whether
virus
unrestrict
replic
exampl
filovirus
easili
adapt
select
exampl
influenza
viru
growth
mice
would
enabl
preclin
studi
earli
product
develop
basi
viral
entri
mechan
tropism
pathogenesi
epidemiolog
consider
vaccin
antigen
design
select
deliveri
approach
could
initi
prototyp
virus
suggest
type
preexist
inform
flavivirus
substanti
acceler
timelin
develop
vaccin
zika
viru
immunologist
virologist
essenti
refin
approach
test
authent
antigen
surfac
exampl
defin
antibodi
lineag
associ
broad
neutral
activ
done
influenza
guid
develop
epitopespecif
germlin
version
b
cell
antigen
raji
cell
serv
tool
screen
antigen
facilit
develop
novel
antigen
influenza
mani
rule
govern
immunogen
vaccin
antigen
display
isol
epitop
yet
defin
antibodi
desir
function
properti
confirm
preserv
target
epitop
vaccin
antigen
critic
part
ration
gene
encod
relev
human
antibodi
also
built
mice
vivo
assess
assay
defin
fundament
mechan
immun
prototyp
pathogen
guid
approach
vaccin
antigen
deliveri
directli
inform
type
assay
need
defin
correl
protect
probabl
distinct
assay
need
surveil
diagnosi
likewis
animalmodel
develop
essenti
import
distinguish
adequaci
model
develop
basic
research
adequaci
model
need
support
regulatori
file
product
licensur
exampl
model
studi
suscept
infect
tropism
pathogenesi
basic
mechan
immun
probabl
use
challeng
rout
dose
differ
use
model
attempt
faith
replic
infecti
exposur
occur
human
refin
facilit
accur
bridg
protect
immun
respons
human
immunogen
data
need
satisfi
requir
licensur
base
anim
efficaci
exampl
us
food
drug
administr
fda
anim
rule
cfr
method
infrastructur
rapid
manufactur
clinic
evalu
candid
vaccin
need
prefer
pathogen
emerg
facilit
develop
platform
technolog
antigen
deliveri
assay
monitor
product
potenc
manufactur
may
differ
substanti
preclin
research
assay
outbreak
set
high
incid
rate
might
quickli
wane
defin
immunolog
correl
protect
determin
laboratori
endpoint
use
clinic
evalu
vaccin
candid
facilit
author
new
product
outbreak
control
region
preapprov
protocol
test
efficaci
outbreak
set
also
improv
chanc
meet
productlicensur
criteria
much
scientif
knowledg
base
infrastructur
particularli
relat
infecti
diseas
built
respons
crisi
epidem
began
zoonot
transmiss
emerg
circul
human
popul
decad
explod
pandem
diseas
fuel
human
mobil
enorm
scientif
effort
understand
pathogenesi
hiv
well
work
develop
antivir
agent
vaccin
major
contributor
evolut
modern
immunolog
hiv
pandem
also
illustr
disrupt
effect
infecti
diseas
economi
social
stabil
clarifi
import
take
global
view
toward
clinic
research
directli
led
develop
substanti
worldwid
clinicaltri
infrastructur
occurr
sever
acut
respiratori
syndrom
sar
coronaviru
ref
threat
avian
influenza
viru
emerg
ref
result
develop
morerobust
laboratori
surveil
network
previous
avail
rapid
success
west
african
ebola
epidem
zika
epidem
south
central
america
caribbean
galvan
organ
concern
eid
focus
attent
media
never
might
polit
support
moreorgan
global
approach
advanc
prepar
next
pandem
threat
much
could
accomplish
within
context
sustain
develop
idea
fund
accomplish
morerapid
advanc
develop
biolog
outbreak
intervent
also
evolv
necess
respons
morefrequ
publichealth
emerg
exampl
within
us
depart
health
human
servic
offic
assist
secretari
prepared
respons
establish
auspic
offic
biomed
advanc
research
develop
author
rapidli
purchas
support
develop
medic
countermeasur
pandem
threat
establish
depart
pandem
epidem
diseas
better
prepar
respond
eid
new
organ
propos
fund
advanc
prepar
vaccin
candid
futur
predict
infecti
diseas
outbreak
global
concern
occur
coalit
epidem
prepared
innov
motiv
larg
ebola
epidem
west
africa
propos
establish
system
fund
develop
vaccin
advanc
next
epidem
prepar
product
process
allow
rapid
deploy
test
outbreak
propos
biodefens
prepared
organ
call
advanc
fund
compani
establish
platform
technolog
could
use
develop
vaccin
pathogen
pandem
potenti
defin
scalabl
commerci
process
evalu
safeti
immunogen
phase
ii
stockpil
substanti
number
dose
efficaci
test
event
futur
therefor
reason
ask
new
technolog
avail
address
emerg
viral
diseas
proactiv
way
learn
recent
outbreak
inform
prepar
futur
infecti
diseas
threat
set
new
pandem
threat
without
advantag
time
prior
knowledg
viral
pathogenesi
experi
viral
growth
attenu
determin
like
tradit
liveattenu
wholeinactiv
vaccin
approach
develop
classic
method
would
rapid
enough
respond
pandem
crisi
therefor
suggest
focu
vaccin
eid
base
newer
genebas
antigendeliveri
technolog
yet
licens
use
human
also
crisi
develop
timelin
need
compress
use
technolog
provid
candid
vaccin
base
inform
deriv
entir
targetgen
sequenc
expediti
procedur
requir
isol
growth
viru
might
requir
highlevel
contain
mean
even
famili
virus
licens
vaccin
addit
approach
beyond
liveattenu
wholeinactiv
vaccin
explor
parallel
convent
vaccin
approach
could
develop
altern
solut
might
need
long
term
typic
vaccin
develop
measur
decad
howev
sinc
new
technolog
evolv
provid
tool
reimagin
acceler
process
vaccin
key
technolog
chang
pace
vaccin
develop
includ
rapid
isol
human
monoclon
abil
defin
atomiclevel
structur
viral
surfac
protein
organ
viral
nextgener
sequenc
character
viru
repertoir
host
immun
method
defin
epitopespecif
immun
cell
phenotyp
precis
singlecel
level
fig
techniqu
identifi
human
monoclon
antibodi
clone
gene
encod
pair
immunoglobulin
heavi
light
chain
sort
b
cell
particularli
transform
method
help
defin
antibodi
lineag
associ
diseas
progress
immun
provid
precis
endpoint
evalu
immunogen
addit
monoclon
antibodi
critic
reagent
assess
antigen
new
immunogen
design
also
develop
clinic
product
passiv
prophylaxi
therapi
also
new
concept
expedit
process
vaccin
discoveri
term
synthet
vaccinolog
appli
sequenc
data
alon
suffici
rapidli
initi
vaccin
antigen
design
product
key
fig
advanc
atomiclevel
protein
understand
assembl
viruslik
particl
vlp
identif
selfassembl
molecul
improv
immunogen
optim
antigen
facilit
fine
tune
vaccineinduc
immun
respons
specif
antigen
target
acceler
develop
evalu
vaccin
requir
new
invest
intern
cooper
platform
technolog
take
advantag
deliveri
approach
establish
manufactur
process
substanti
preexist
safeti
databas
human
could
shorten
timelin
manufactur
uniform
chemic
manufactur
control
section
investig
new
drug
applic
acceler
preclin
toxicolog
fig
major
focu
coalit
epidem
prepared
innov
new
concept
biodefens
prepared
organ
mention
indic
need
recogn
infrastructur
invest
establish
like
multipl
distinct
platform
vaccin
technolog
need
address
divers
viral
pathogen
diseas
manifest
addit
process
put
product
vial
need
improv
commun
cooper
across
border
acceler
regulatori
review
new
product
organ
like
african
vaccin
regulatori
forum
expand
across
globe
product
enter
efficaci
evalu
rapidli
midst
crisi
within
famili
virus
associ
human
infect
tabl
multipl
genera
speci
could
better
defin
modern
sequenc
technolog
full
rang
known
viral
pathogen
defin
sequenc
could
categor
accord
entri
mechan
tropism
rout
transmiss
select
finit
number
repres
virus
serv
prototyp
newli
emerg
virus
compar
identifi
potenti
vaccin
strategi
might
one
prototyp
viru
famili
taxonomi
evolv
exampl
like
vaccin
approach
orthomyxoviru
influenza
viru
distinct
tickborn
bourbon
viru
also
orthomyxoviru
due
differ
transmiss
rout
tropism
convers
pneumovirida
famili
split
paramyxovirida
famili
subtl
differ
fusionprotein
structur
genom
organ
regulatori
protein
common
vaccin
approach
might
applic
ebola
crisi
west
africa
zika
outbreak
south
central
america
caribbean
reveal
sever
critic
featur
global
health
infrastructur
capac
respond
infecti
diseas
emerg
outbreak
arriv
context
pandem
well
multipl
instanc
newli
recogn
acut
viral
diseas
chikungunya
region
zika
addit
known
diseas
occur
new
popul
distinct
epidemiolog
featur
exemplifi
extens
ebola
epidem
west
africa
mer
result
sarslik
betacoronaviru
caus
sporad
outbreak
sever
respiratori
diseas
particularli
healthcar
set
biolog
technic
geopolit
hurdl
overcom
emerg
respons
event
driven
substanti
advanc
overal
understand
viral
pathogenesi
immun
respons
although
delay
usher
modern
era
immunolog
fund
scientif
effort
devot
biolog
prevent
infect
viru
provid
mani
tool
need
eid
genebas
vaccin
includ
nucleicacid
vector
approach
multiparamet
flow
cytometri
better
definit
phenotyp
function
cell
involv
immun
multipl
techniqu
isol
neutral
human
monoclon
antibodi
applic
atomiclevel
structur
antigen
design
definit
b
cell
clonal
lineag
way
understand
ontogeni
effect
antibodi
respons
aros
wide
use
technolog
consequ
broad
intens
research
combat
hiv
respons
ebola
zika
notabl
exampl
acceler
rapid
respons
concert
effort
develop
test
experiment
vaccin
candid
field
outbreak
use
intervent
tool
understand
condit
respons
feasibl
addit
awar
technolog
tool
current
avail
might
improv
abil
util
vaccin
futur
outbreak
threaten
public
health
sinc
discoveri
zair
ebolaviru
relat
filovirus
sudan
ebolaviru
marburgviru
caus
sporad
outbreak
affect
order
hundr
peopl
within
geograph
limit
area
outbreak
alarm
indic
filovirus
abl
spread
larg
epidem
urban
center
rural
area
ebola
reemerg
kikwit
epidem
work
filoviru
pathogenesi
immun
vaccin
develop
carri
rel
investig
need
biosafeti
level
contain
space
limit
commerci
interest
support
advanc
develop
chang
greater
emphasi
place
biodefens
research
result
anthrax
attack
postal
facil
govern
offic
us
govern
recogn
gap
prepared
natur
intent
exposur
highli
lethal
pathogen
oper
bioshield
launch
mechan
fund
research
develop
countermeasur
list
specif
highli
lethal
agent
categori
pathogen
research
fund
complement
new
rule
us
fda
facilit
licensur
vaccin
therapeut
anim
data
sinc
efficaci
vaccin
direct
categori
lethal
pathogen
evalu
easili
human
fda
anim
rule
cfr
propos
provid
pathway
regulatori
review
biolog
countermeasur
pathogen
basi
efficaci
studi
anim
instead
human
definit
immunolog
correl
protect
welldefin
anim
model
recapitul
pathogenesi
human
diseas
bridg
studi
human
safeti
immunogen
increas
support
identifi
intervent
pathogen
potenti
use
biowarfar
new
regulatori
option
clinic
develop
led
first
phase
evalu
candid
vaccin
ebola
viru
ref
seri
subsequ
clinic
trial
dna
recombin
adenoviru
vector
vaccin
proceed
ensu
year
includ
optim
vaccin
compon
refin
surfaceglycoproteinantigen
design
extens
studi
vaccin
efficaci
correl
immun
guid
develop
parallel
substanti
advanc
understand
structur
entri
mechan
replic
strategi
pathogenesi
ebola
viru
inform
design
vaccin
clinic
trial
cours
two
decad
basic
research
pathogenesi
immunolog
correl
protect
togeth
clinic
evalu
safeti
immunogen
phase
trial
form
critic
safeti
databas
foundat
knowledg
allow
rapid
entri
new
candid
vaccin
ebola
viru
advanc
clinic
evalu
outbreak
exampl
final
lead
adenovirusbas
vaccin
candid
enter
phase
evalu
septemb
within
month
declar
public
health
emerg
intern
concern
cooper
effort
multipl
govern
agenc
regulatori
author
funder
worldwid
consortium
site
help
expand
safeti
immunogen
databas
allow
product
enter
efficaci
evalu
liberia
februari
ref
establish
safeti
data
ebola
viru
glycoprotein
antigen
human
also
facilit
rapid
advanc
glycoproteinexpress
vaccin
vector
test
human
includ
recombin
vesicular
stomat
viru
rvsv
success
evalu
efficaci
guinea
ref
despit
effort
rapid
deploy
vector
complet
efficaci
test
liberia
incid
case
ebola
howev
rvsv
vaccin
found
efficaci
steppedwedg
ringvaccin
design
guinea
outbreak
continu
month
achiev
efficaci
result
possibl
prior
basic
clinic
research
also
vaccin
rvsv
vaccin
manufactur
vial
current
good
manufactur
practic
outbreak
west
africa
prior
invest
us
govern
canadian
govern
respect
ebola
experi
rapid
intern
respons
global
public
health
emerg
illustr
benefit
prepar
defin
immunolog
determin
vaccin
protect
highli
lethal
pathogen
animalmodel
develop
phase
safeti
immunogen
data
industri
involv
manufactur
vaccin
avail
immedi
use
howev
also
expos
gap
inform
plan
requir
effect
use
vaccin
interven
midst
public
health
crisi
effort
acceler
avail
vaccin
ebola
viru
west
african
epidem
extraordinari
unpreced
use
consid
step
could
taken
advanc
make
vaccin
avail
quickli
ideal
vaccin
would
alreadi
licens
gener
use
basi
anim
rule
would
preauthor
emerg
use
region
regulatori
author
stockpil
suffici
quantiti
epidem
altern
unlicens
experiment
vaccin
prepar
use
human
current
good
manufactur
practic
could
stockpil
suffici
quantiti
clinic
protocol
consent
document
could
preapprov
region
regulatori
agenc
expand
use
therefor
clinic
infrastructur
avail
rapid
deploy
evalu
vaccin
could
accomplish
sinc
achiev
licensur
tradit
pathway
random
clinic
phase
iii
efficaci
trial
unlik
absenc
ongo
consist
endem
transmiss
provis
licensur
anim
rule
preoutbreak
approv
clinic
efficaci
test
new
outbreak
proactiv
establish
sinc
discoveri
ziika
forest
uganda
zika
viru
occasion
recogn
caus
mild
denguelik
syndrom
fever
caus
outbreak
yap
island
emerg
french
polynesia
current
region
outbreak
start
late
brazil
caus
outbreak
recogn
zika
viru
may
associ
fetal
infect
neurolog
disord
identifi
earli
declar
global
health
unlik
respons
ebola
zika
preexist
basic
clinic
research
program
candid
vaccin
avail
outbreak
emerg
product
author
immedi
use
possibl
although
bharat
biotech
hyderabad
india
recogn
potenti
need
vaccin
zika
viru
french
polynesia
outbreak
vaccin
develop
acceler
parallel
varieti
platform
technolog
advanc
rapidli
basi
extens
inform
avail
work
member
flavivirida
includ
substanti
bodi
knowledg
viral
mechan
antibodi
well
preced
success
vaccin
vaccin
base
nucleicacid
platform
technolog
avail
vectorbas
approach
tradit
platform
use
wholeinactiv
viru
liveattenu
viru
live
chimer
virus
far
behind
develop
anim
model
rapidli
serolog
diagnost
test
monoclon
antibodi
basic
aspect
flavivirusspecif
virolog
confirm
includ
atomiclevel
larg
naturalhistori
epidemiolog
studi
initi
within
month
time
announc
public
health
emerg
intern
concern
phase
clinic
trial
initi
phase
iib
efficaci
evalu
earli
candid
began
within
month
model
transmiss
dynam
anticip
trial
site
locat
tri
captur
mosquito
season
southern
hemispher
northern
hemispher
use
infect
well
clinic
symptom
endpoint
might
increas
likelihood
achiev
efficaci
result
note
move
advanc
clinic
studi
rapidli
would
requir
preapprov
vaccinedeliveri
platform
region
efficaci
protocol
addit
mainten
global
clinic
trial
infrastructur
could
access
short
notic
centuri
human
face
extraordinari
challeng
known
emerg
viral
pathogen
due
increas
likelihood
transmiss
zoonot
vectorborn
human
sourc
fortun
technic
abil
identifi
potenti
viral
threat
understand
viral
pathogen
atom
level
precis
avail
prospect
invest
repres
costsav
measur
compar
expenditur
requir
emerg
respons
requir
advocaci
sustain
polit
support
advanc
prepar
necessari
prevent
rapidli
respond
next
global
pandem
surveil
unit
special
highthroughput
sequenc
establish
select
locat
around
globe
ecosystem
divers
unit
could
support
clinic
care
improv
region
diagnost
capabl
could
also
engag
discoveri
research
probe
sampl
patient
fever
rash
unknown
origin
sampl
domest
wild
anim
evid
contagion
urin
collect
wild
rodent
bat
content
mosquito
bite
insect
primer
could
captur
sequenc
famili
virus
greatest
concern
might
addit
famili
virus
arterivirida
caus
consider
veterinari
diseas
present
potenti
zoonot
risk
sinc
known
simian
virus
within
order
nidoviral
within
relev
famili
virus
databas
inform
accompani
reagent
assay
develop
prototyp
virus
basi
properti
tropism
transmiss
rout
distinguish
featur
pathogenesi
structur
candid
vaccin
approach
could
design
basi
featur
overal
viral
structur
transmiss
dynam
entri
requir
tropism
replic
strategi
could
evalu
small
anim
immunogen
protect
challeng
feasibl
step
manufactur
candid
vaccin
clinic
evalu
immedi
market
difficult
hurdl
overcom
perspect
intermedi
option
could
includ
manufactur
evalu
least
one
product
major
technolog
platform
stage
phase
ii
clinic
test
rather
famili
subgroup
virus
exampl
step
involv
construct
manufactur
product
use
genebas
antigen
deliveri
nucleic
acid
replicationdefect
vector
might
envelop
glycoprotein
function
trimer
class
fusion
machin
regardless
specif
viru
likewis
step
involv
scale
product
vlp
virus
icosahedr
capsid
might
similar
preced
manufactur
particular
type
product
next
crisi
occur
would
improv
respons
time
howev
extent
possibl
viru
even
within
taxonom
famili
uniqu
characterist
develop
ration
candid
vaccin
direct
least
one
prototyp
viru
within
major
phenotyp
categori
within
famili
virus
advis
tabl
new
partnership
model
accomplish
task
use
public
fund
privat
fund
might
need
model
includ
governmenttogovern
collabor
nonprofit
organ
philanthropi
partnership
experi
ebola
zika
taught
media
coverag
wane
pressur
public
health
crisi
diminish
polit
corpor
commit
longterm
vaccinedevelop
effort
waver
knowledg
accumul
across
pathogen
platform
organ
work
group
span
virus
share
featur
entri
mechan
whether
viru
lipid
envelop
might
use
likewis
establish
group
appli
particular
platform
technolog
design
manufactur
vaccin
across
multipl
pathogen
might
creat
synergi
program
could
also
design
around
function
categori
virus
larg
conceptu
gap
knowledg
describ
follow
four
exampl
vlp
licens
platform
human
papillomaviru
hepat
b
viru
hepat
e
viru
extrem
effect
immunogen
safe
manufactur
administr
therefor
reason
assum
nonenvelop
virus
icosahedr
capsid
especi
bloodborn
phase
part
pathogenesi
viru
like
suscept
neutral
antibodi
order
antigen
array
particl
one
potent
mechan
induc
strong
antibodi
respons
produc
authent
structur
nativ
capsid
vlp
approach
use
either
proteinbas
deliveri
genebas
deliveri
would
ideal
famili
virus
envelop
virus
choos
platform
vaccin
approach
straightforward
protein
set
protein
allow
mediat
membran
fusion
often
key
target
neutral
antibodi
therefor
protein
attract
vaccin
target
envelop
viru
interest
known
sensit
neutral
fusion
protein
complex
isol
stabil
present
appropri
conform
vlp
nanoparticl
subunitproteinvaccin
approach
deliv
protein
geneencod
antigen
would
ration
work
group
special
design
antigen
class
ii
iii
fusion
protein
might
use
within
area
work
mani
envelop
virus
complex
pathogenesi
might
requir
neutralizingantibodi
respons
ideal
type
virus
poxvirus
filovirus
neutralizingantibodi
respons
cellmedi
respons
capabl
clear
virusinfect
cell
limit
spread
viru
escap
front
line
antibodi
defens
might
need
adequ
immun
case
genebas
antigen
deliveri
use
nucleic
acid
singleround
replicationdefect
whole
viru
vectordeliv
antigen
might
need
primari
induct
protect
respons
work
group
focus
induct
regul
cell
immun
would
use
virus
particularli
adept
avoid
escap
immun
system
factor
extrem
genet
plastic
antigen
variabl
hiv
influenza
viru
multipl
distinct
serotyp
rhinovirus
persist
infect
latenc
hiv
herpesvirus
new
strategi
need
develop
antigen
design
formul
rout
sequenc
time
deliveri
combin
modal
achiev
suffici
breadth
durabl
make
vaccin
develop
practic
solv
biolog
challeng
difficult
viral
pathogen
might
provid
solut
could
use
prepandem
vaccin
develop
rapid
vaccin
develop
respons
emerg
viral
pathogen
suggest
work
group
scientif
consortia
assembl
around
larger
concept
design
vaccin
antigen
induc
broadli
crossreact
antibodi
vaccinedeliveri
approach
establish
select
immun
effector
target
tissu
locat
prepar
emerg
viral
diseas
inher
compon
achiev
un
sdg
requir
contribut
multipl
disciplin
includ
immunolog
despit
impend
threat
pandem
diseas
emerg
virus
abil
technolog
tool
avail
achiev
substanti
level
advanc
prepar
next
major
event
systemat
effort
sustain
effect
intervent
major
futur
pathogen
develop
